Solid Biosciences (NASDAQ:SLDB) and Pluristem Therapeutics (NASDAQ:PSTI) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, risk, earnings, dividends, valuation, profitability and analyst recommendations.

Insider & Institutional Ownership

63.7% of Solid Biosciences shares are held by institutional investors. Comparatively, 5.2% of Pluristem Therapeutics shares are held by institutional investors. 7.2% of Pluristem Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Solid Biosciences and Pluristem Therapeutics’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Solid Biosciences N/A N/A -$52.11 million ($2.88) -11.03
Pluristem Therapeutics $50,000.00 2,524.44 -$26.12 million ($0.25) -4.36

Pluristem Therapeutics has higher revenue and earnings than Solid Biosciences. Solid Biosciences is trading at a lower price-to-earnings ratio than Pluristem Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Solid Biosciences and Pluristem Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Solid Biosciences N/A -63.10% -45.38%
Pluristem Therapeutics N/A -91.60% -69.89%

Analyst Recommendations

This is a summary of current ratings and recommmendations for Solid Biosciences and Pluristem Therapeutics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Solid Biosciences 2 2 4 0 2.25
Pluristem Therapeutics 0 0 4 0 3.00

Solid Biosciences presently has a consensus target price of $42.63, suggesting a potential upside of 34.17%. Pluristem Therapeutics has a consensus target price of $3.83, suggesting a potential upside of 251.68%. Given Pluristem Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Pluristem Therapeutics is more favorable than Solid Biosciences.

Summary

Pluristem Therapeutics beats Solid Biosciences on 7 of the 10 factors compared between the two stocks.

About Solid Biosciences

Solid Biosciences Inc. engages in identifying and developing therapies for duchenne muscular dystrophy in the United States. Its lead product candidate includes SGT-001, a gene therapy that is in Phase I/II clinical trials to restore functional dystrophin protein expression in patients' muscles. The company's product candidates also comprise SB-001, a monoclonal antibody to reduce fibrosis and inflammation. In addition, it is developing soft wearable assistive devices that have functional and therapeutic benefits to DMD patients. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

About Pluristem Therapeutics

Pluristem Therapeutics Inc., together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops PLacental eXpanded (PLX) cell therapy products, including PLX-PAD cells, which is Phase III clinical trial for the treatment of critical limb ischemia (CLI) in patients ineligible for revascularization, recovery after surgery for hip fracture, and acute radiation syndrome (ARS), as well as peripheral and cardiovascular, and orthopedic diseases. It also develops PLX-R18 cells that is in Phase I clinical trial for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of ARS. The company has collaborative research agreement with the Berlin-Brandenburg Center for Regenerative Therapies; a license and commercialization agreement for conducting clinical trials and commercialization of its PLX-PAD product in South Korea related to the treatment CLI and intermediate claudication; and nTRACK, a collaborative project with Leitat to examine gold nano particles labeling of stem cells. Pluristem Therapeutics Inc. was founded in 2001 and is based in Haifa, Israel.

Receive News & Ratings for Solid Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solid Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.